NCT04703634

Brief Summary

The main purpose of this study is to evaluate the postoperative effect of erector spinae block in patients undergoing nephrectomy that causes both visceral and somatic pain.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Jan 2021

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 6, 2021

Completed
5 days until next milestone

First Posted

Study publicly available on registry

January 11, 2021

Completed
3 days until next milestone

Study Start

First participant enrolled

January 14, 2021

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 17, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 17, 2021

Completed
Last Updated

September 1, 2021

Status Verified

August 1, 2021

Enrollment Period

4 months

First QC Date

January 6, 2021

Last Update Submit

August 31, 2021

Conditions

Keywords

erector spinae blocknephrectomyultrasound

Outcome Measures

Primary Outcomes (1)

  • Numerical Rating Scale (NRS)

    Numerical Rating Scale (NRS) will be used for postoperative evaluation. NRS is a segmented digital version of the visual analog scale. Selecting an integer (0-10 integers) by a responder in (VAS). It is accepted as one dimensional-the measure of pain intensity in adults. The 11-point numerical scale ranges from "0" to "10," representing a pain ("no pain"). 10 ("as bad pain as you can imagine"), or ("the worst pain imaginable").

    24 hours

Secondary Outcomes (2)

  • Recovery analgesia

    24 hours

  • postoperative nausea and vomiting

    24 hours

Study Arms (2)

erector spinae group

EXPERIMENTAL

All blocks will be done under general anesthesia. Using a 6-10 MHz linear ultrasound (Esaote my-lab 6, Italy). With the ultrasonography device of our clinic, the side of the nephrectomy surgery will be performed with the position of the nephrectomy, and the position (lateral decubitus) is given to the patient. The thoracic 10th vertebra will be found under ultrasound guidance. After the T12 transverse protrusion is seen by sliding 3 cm laterally from the midline, 30 ml of 0.25% Bupivacaine will be injected under the erector spinae muscle above it.

Procedure: erector spinae block (ESP)

placebo group

PLACEBO COMPARATOR

No block transaction will be applied to this group. Only postoperative analgesia methods will be used for this group as specified in the protocol.

Procedure: erector spinae block (ESP)

Interventions

Administration of local anesthetic under the erector spinae muscle just below the transverse process of the thoracic 12th vertebra

erector spinae groupplacebo group

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • To undergo partial or total nephrectomy surgery
  • To be in ASA I-II classification
  • To be between the ages of 18-65.
  • Not having problems that prevent erector spinae block application such as local anesthetic drug allergy, infection at the injection site, and structural anomaly.
  • Being in good mental and psychological health
  • To accept to participate in the study.

You may not qualify if:

  • Being in ASA III or IV class with a high risk of anesthesia
  • Being outside the age range of 18-65
  • Having problems such as local anesthetic drug allergy, infection at the injection site, and structural anomaly prevents block application.
  • Not being mentally and psychologically healthy
  • Those who are allergic to the active substance, patients using antiepileptic drugs
  • Those with severe hepatic and renal failure
  • Those who have long-term use of nonsteroidal anti-inflammatory and opioid analgesic,
  • Those with diabetes and other neuropathic diseases
  • Patients who cannot use patient-controlled analgesia (PCA) device

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Namık Kemal University

Tekirdağ, Süleymanpaşa, 59100, Turkey (Türkiye)

Location

Study Officials

  • Ayhan ŞAHİN

    Namık Kemal University Medicine Faculty

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Model Details: It is a single centre, randomized, prospective method comparison study.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Asistant Prof

Study Record Dates

First Submitted

January 6, 2021

First Posted

January 11, 2021

Study Start

January 14, 2021

Primary Completion

May 17, 2021

Study Completion

May 17, 2021

Last Updated

September 1, 2021

Record last verified: 2021-08

Data Sharing

IPD Sharing
Will share

Participant data will be shared as much as the tasks described in the study. A meeting will be held at the end of the research, and the statistical data results will be shared. Dr. Ayhan Şahin is responsible.

Shared Documents
STUDY PROTOCOL, SAP
Time Frame
starting after 6 months publication
Access Criteria
After publication, sharing will be made according to the journal criteria.

Locations